Company to host conference call on
Monday, October 3rd at
8:30 a.m. ET to discuss new, interim
data from the ongoing Phase II AAVIATE® trial
ROCKVILLE, Md., Sept. 26,
2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced presentations at the American Academy of
Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 in Chicago, IL. The presentations will highlight
new and encore data for RGX-314, an investigational one-time AAV
Therapeutic being developed in collaboration with AbbVie for the
treatment of wet age-related macular degeneration, diabetic
retinopathy and other additional chronic retinal conditions.
Presentations include:
Title: Subretinal RGX-314 Gene Therapy: Phase I/IIa
Long-Term Follow-Up Results up to 4 Years
Presenter: Peter A.
Campochiaro, M.D., Director, Retinal Cell and Molecular
Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute,
Johns Hopkins University School of
Medicine
Date/Time: Saturday, October 1,
2022, 2:25 CDT
Title: Suprachoroidal Delivery of RGX-314 Gene Therapy
for Diabetic Retinopathy: The Phase 2 ALTITUDE Study (encore)
Presenter: Arshad Khanani
M.D., M.A, Managing Partner, Director of Clinical Research,
Sierra Eye Associates, Clinical Associate Professor, University of Nevada, Reno School of Medicine
Date/Time: Sunday, October 2, 2022, 3:45 CDT
On Monday, October 3 at
8:30 a.m. ET, REGENXBIO also plans to
host a conference call to provide a new, interim update from the
ongoing Phase II AAVIATE® trial of RGX-314 for the
treatment of wet AMD using suprachoroidal delivery. Details for the
call will follow.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-upcoming-presentations-during-the-american-academy-of-ophthalmology-2022-annual-meeting-301632748.html
SOURCE REGENXBIO Inc.